Dermatology Advisor6d
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Yahoo Finance25d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Specifically, for YESINTEK the study shows that it offers an effective, safe, and comparable alternative to reference Ustekinumab in the treatment of moderate to severe chronic plaque psoriasis ...
Hosted on MSN22d
This new study offers greater relief to India's psoriasis patients, hopefully
"We are thrilled to share the pivotal Phase 3 study results comparing our biosimilar bUstekinumab with the reference product Stelara (Ustekinumab) in adult patients with moderate to severe chronic ...
Inquirer Opinion on MSN1d
Lifelong itch
My first experience with the condition was in my third year in high school. It started as subtle red bumps along my hairline, which gradually turned scaly. Soon after, I was experiencing dandruff, and ...
Medical Dialogues12d
Psoriasis Patients at Higher Risk of Metabolic and Cardiovascular Conditions, Study Shows
The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...
European Medical Journal4d
Spesolimab: A Breakthrough in Treating Generalised Pustular Psoriasis
Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...
Pharm Exec22d
Icotrokinra Demonstrates Promise in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints. Johnson & Johnson’s ...
Medscape4d
Etanercept Injection Site Reaction
It is approved for use in rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and adults with chronic moderate-to-severe plaque psoriasis. In clinical ...
Medscape12d
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
Morningstar25d
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
in adults with moderate-to-severe plaque psoriasis (PSO). Dual inhibition with BIMZELX demonstrated high efficacy and sustained clinical benefits across different adult patient populations living ...
Medindia25d
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...